SynthesisFrontiers in oncology2024
The role of preoperative serum thyroglobulin in the diagnosis and treatment of differentiated thyroid cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Association of Anti-TPO Antibody and Inflammatory Markers with Thyroid Ultrasound FindingsEndocrine, metabolic & immune disorders drug targets · 2026Article
- Predictive value of preoperative serum thyroglobulin and anti-thyroglobulin antibodies for central compartment lymph node metastasis in cN0 papillary thyroid carcinoma.Frontiers in molecular biosciences · 2026Article
- Comparative analysis of three thyroglobulin immunoassays: analytical performance and clinical implications.Thyroid research · 2025Article
- A nomogram for predicting the central lymph node metastasis in double primary carcinoma involving thyroid carcinoma.Gland surgery · 2025Article
- Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serum thyroglobulin (Tg) is a critical marker for monitoring tumor recurrence and metastasis in patients who have undergone total thyroidectomy for differentiated thyroid cancer (DTC). While the definitive role of preoperative serum Tg in DTC is not yet established, studies suggest its importance in differentiating between benign and malignant thyroid nodules with indeterminate cytology, as well as in predicting distant metastasis (DM) in patients with DTC. Methods: A thorough literature review was conducted on the use of preoperative serum Tg in differentiating between benign and malignant thyroid nodules, and in evaluating the extent of DTC lesions. Relevant studies were systematically searched in PubMed, Embase, Cochrane, Scopus, and ClinicalTrials databases. A meta-analysis was performed on studies where the ratios between serum Tg diagnostic thresholds and the upper limit of the reference range were similar. Results: Recent studies showed significantly elevated preoperative serum Tg levels in patients with DTC compared with normal individuals. However, there are inconsistencies in the serum Tg levels between patients with preoperative DTC and benign thyroid nodules across different studies. In patients with thyroid nodules who had indeterminate cytology (negative Tg antibody), the preoperative serum Tg levels were significantly higher in malignant nodules than in benign ones (meta-analysis: odds ratio: 2.59, 95% confidence intervals: 1.59-4.21, P = 0.0001). Although the meta-analysis indicated that high preoperative serum Tg is a risk factor for central lymph node metastasis in patients with DTC (meta-analysis: odds ratio: 1.68, 95% confidence interval: 1.32-2.14, P < 0.0001), some studies suggest that high preoperative serum Tg in patients with DTC does not necessarily lead to central lymph node metastasis. Furthermore, preoperative serum Tg might possess a suggestive value regarding the likelihood of DTC patients developing DM. Conclusion: Preoperative serum Tg shows promise in differentiating between benign and malignant nodules in thyroid nodule patients with indeterminate cytology. However, further research is necessary to determine its predictive significance for lymph node metastasis and DM in patients with DTC. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/#searchadvanced, identifier CRD42024472074.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.